Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Therapy With Porfimer Sodium in Malignant Bile Duct Obstruction
NCT00003923Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 1999
- Primary completion
- Feb 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of porfimer sodium in bile duct obstruction, cholangiocarcinoma (CCA), gallbladder cancer and 1 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Safety at 1 year and Efficacy at 1 year. Started Mar 1999; status: completed.
02
Drugs
porfimer sodium
03
Conditions
bile duct obstructioncholangiocarcinoma (CCA)gallbladder cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00003923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003923.